Immunovant Inc (IMVT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 03/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -357,750 | -247,115 | -120,613 | -413,840 | -307,391 |
| Depreciation Amortization | 313 | 212 | 107 | 377 | 268 |
| Accounts receivable | 423 | 104 | 129 | 3,232 | 3,147 |
| Accounts payable and accrued liabilities | -8,903 | -10,466 | -9,401 | 10,939 | 12,988 |
| Other Working Capital | 530 | -4,939 | -15,439 | -12,031 | 3,975 |
| Other Operating Activity | 53,136 | 42,278 | 27,806 | 35,449 | 21,776 |
| Operating Cash Flow | $-312,251 | $-219,926 | $-117,411 | $-375,874 | $-265,237 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | N/A | N/A | N/A | -759 | -558 |
| Investing Cash Flow | $N/A | $N/A | $N/A | $-759 | $-558 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 592,702 | 27,513 | 2,918 | 454,811 | 3,880 |
| Other Financing Activity | -586 | 0 | 0 | -319 | 0 |
| Financing Cash Flow | $592,116 | $27,513 | $2,918 | $454,492 | $3,880 |
| Exchange Rate Effect | 689 | 312 | -566 | 747 | 1,235 |
| Beginning Cash Position | 713,971 | 713,971 | 713,971 | 635,365 | 635,365 |
| End Cash Position | 994,525 | 521,870 | 598,912 | 713,971 | 374,685 |
| Net Cash Flow | $280,554 | $-192,101 | $-115,059 | $78,606 | $-260,680 |
| Free Cash Flow | |||||
| Operating Cash Flow | -312,251 | -219,926 | -117,411 | -375,874 | -265,237 |
| Capital Expenditure | N/A | N/A | N/A | -759 | -558 |
| Free Cash Flow | -312,251 | -219,926 | -117,411 | -376,633 | -265,795 |